



GL®BAL Monthly Report

Foot-and-Mouth Disease

Foot-and-Mouth Disease Situation | 2019 | April









Foot-and-Mouth Disease Situation

Food and Agriculture Organization of the United Nations Monthly Report

April 2019

MAIN INFORMATION SOURCES	U S E D:

The sources for information are referenced by using superscripts.

The key to the superscripts is on the last page.

Please note that the use of information and boundaries of territories should not be considered to be the view of the U.N. Please, always refer to the OIE for official information on reported outbreaks and country status.

Required citation:

FAO/EuFMD. 2019. Global Monthly Report. Foot-and-Mouth Disease Situation April 2019. Rome, FAO.

The designations employed and the presentation of material in this information product do not imply the expression of any opinion whatsoever on the part of the Food and Agriculture Organization of the United Nations (FAO) concerning the legal or development status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. The mention of specific companies or products of manufacturers, whether or not these have been patented, does not imply that these have been endorsed or recommended by FAO in preference to others of a similar nature that are not mentioned.

The views expressed in this information product are those of the author(s) and do not necessarily reflect the views or policies of FAO.

© FAO, 2019



Some rights reserved. This work is made available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo/legalcode).

Under the terms of this licence, this work may be copied, redistributed and adapted for non-commercial purposes, provided that the work is appropriately cited. In any use of this work, there should be no suggestion that FAO endorses any specific organization, products or services. The use of the FAO logo is not permitted. If the work is adapted, then it must be licensed under the same or equivalent Creative Commons licence. If a translation of this work is created, it must include the following disclaimer along with the required citation: "This translation was not created by the Food and Agriculture Organization of the United Nations (FAO). FAO is not responsible for the content or accuracy of this translation. The original [Language] edition shall be the authoritative edition."

Disputes arising under the licence that cannot be settled amicably will be resolved by mediation and arbitration as described in Article 8 of the licence except as otherwise provided herein. The applicable mediation rules will be the mediation rules of the World Intellectual Property Organization http://www.wipo.int/amc/en/mediation/rules and any arbitration will be conducted in accordance with the Arbitration Rules of the United Nations Commission on International Trade Law (UNCITRAL).

Third-party materials. Users wishing to reuse material from this work that is attributed to a third party, such as tables, figures or images, are responsible for determining whether permission is needed for that reuse and for obtaining permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

Sales, rights and licensing. FAO information products are available on the FAO website (www.fao.org/publications) and can be purchased through publications-sales@fao.org. Requests for commercial use should be submitted via: www.fao.org/contact-us/licence-request. Queries regarding rights and licensing should be submitted to: copyright@fao.org.



ı.	HIGHLIGHTS
_	

Actions to Outbreaks and Emerging FMD Serotypes"	"Response

II. GENERAL OVERVIEW

Pools represent independently circulating and evolving genotypes; within the pools, cycles of emergence and spread occur that usually affect multiple countries in the region. In the absence of specific reports, it should be assumed that the serotypes indicated below are continuously circulating in parts of the pool area and would be detected if sufficient surveillance was in place (Table 1).

Table 1:

POOL	REGION/COUNTRIES – colour pools as in Map	SEROTYPES
1	SOUTHEAST ASIA/CENTRAL ASIA/EAST ASIA	A, Asia 1 and O
2	<u>SOUTH ASIA</u>	A, Asia 1 and O
3	WEST EURASIA & MIDDLE EAST	A, Asia 1 and O (SAT 2)*
	NORTH AFRICA	A, O and SAT 2
4	EASTERN AFRICA	O, A, SAT 1, SAT 2 and SAT 3
5	WEST/CENTRAL AFRICA	O, A, SAT 1 and SAT 2
6	SOUTHERN AFRICA	{O, A}**, SAT 1, SAT 2 and SAT 3
7	SOUTH AMERICA	O and A

III. IN THIS REPORT

POOL 1- SOUTHEAST ASIA/CENTRAL ASIA/EAST ASIA
China ¹ –
POOL 2 - SOUTH ASIA
Bhutan ² –
POOL 3 - WEST EURASIA & MIDDLE EAST
Afghanistan ³
Israel ²
Pakistan ⁴ –
Palestine ²
POOL 3 – NORTH AFRICA
Algeria ² –
Egypt ² –
Morocco ²
Libya ¹
Tunisia ² –
POOL 4 - EASTERN AFRICA
Comoros ¹ –
Ethiopia ^{2, 5}

Kenya ⁶
POOL 5 - WEST/CENTRAL AFRICA
Cote d'Ivoire ²
Ghana ²
Guinea ² –
Guinea-Bissau ¹
Mauritania ²
POOL 6 - SOUTHERN AFRICA
Zambia ²
POOL 7 - SOUTH AMERICA 1, 7

*** 177 MONTHS SINCE THE LAST SEROTYPE C OUTBREAK WAS REPORTED

COUNTER

IV. DETAILED POOL ANALYSIS


A. POOL 1 – <u>SOUTHEAST ASIA/CENTRAL ASIA/EAST ASIA</u>

OUTBREAL	OUTBREAKS						
Country	Description						
Serotype O in China ¹							
O in							
China 1							
	<u>Interpretation</u>						


SURVEILLANCE (Surv.), VACCINATION (Vacc.) AND POST VACCINATION MONITORING (PVM)					
Country	Activity	Description			
Russian					
Federation					
<u>1</u>					

Table 2 and Graph 1

Serotype	Viral lineage	Number of countries where strain is believed to circulate in the 13 countries of Pool 1



Graph 2:




B. POOL 2 - South Asia


_

Table 3 and Graph 3:


Serotype	Viral lineage	Number of countries where strain is believed to circulate the 5 countries of Pool 2			



Graph 4:



C. POOL 3 - West Eurasia & Middle East




OUTBREAKS									
	Table 4:						Dr. Mul	hammad Af	īzal
			•	,					
	Duranta ar	Number -	Number (%) of Outbreaks due to FMD Virus Serotype(s)						
	Province	District	Outbreaks	'0'	'A'	'Asia-1'	'Mixed'	Negative	Not yet typed
	Total		244	20 (40%)	4((8%)	21 (42%)	5 (10%)	45	149
	l				., ,				

OUTDDEAKS


Country	Activity	Description		
Afghanistan				
srael ²				
Palestine ²				
Pakistan ⁴		Province	Ring Vaccination (Doses)	
		Total	37,675	

Table 5 and Graph 5

Serotype	Viral lineage	Number of countries where strain is believed to circulate in the 24 countries of Pool 3 - West Eurasia



Graph 6:




D. POOL 3 – North Africa

OUTBREA	KS .
Country	Description
<u>Serotype</u>	
pending	
<u>in</u> Libya ¹	
<u>Libya</u> ¹	
	Interpretation
	merpretation


SURVEILLA	NCE (Surv.)	, VACCINATION	(Vacc.) AND POST V	ACCINATI	ON MONI	TORING (F	PVM)	
Country	Activity	Description						
Algeria ²								
		Table 6						
		Table 0						
		Sample Identification	Location of origin of sample	Host species	Date of collection	Genotype	Most Closely Related Viruses not pertaining to the country- Seq id %	Host species

Map 2



Egypt ²

Map 3



Morocco					
3=					
	Map 4				
	Google Earth Programmer Copyright One Sco, NOAA, USINNY, NOA, CEECO		Rabat Khouri Bennour Sidi Ber	Alboran	Alba Mountains 700 km
	Administrative division	Species	Total Vaccinated	Number of farms	
	Total		55,500	10,918	
Tunisia ²					






Table 8 and Graph 7:


Serotype	Viral lineage	Number of countries where strain is believed to circulate in the 5 countries of Pool 3 - North Africa



Graph 8:



E. POOL 4 – Eastern Africa



Serotypes
A and
SAT 2 in
Ethiopia 5

Interpretation:
Map 7

Interpretation:
Map 4

Interpretation:
Map 4


Interpretation:

In


SURVEILLA	SURVEILLANCE (Surv.), VACCINATION (Vacc.) AND POST VACCINATION MONITORING (PVM)			
Country	Activity	Description		
Ethiopia				
2				
Kenya ⁶				

Table 9 and Graph 9:

Serotype	Viral lineage	Number of countries where strain is believed to circulate in the 13 countries of Pool 4 East Africa



Graph 10:



F. POOL 5 - West / Central Africa


Country	Description
Serotype O	
<u>in</u>	
Guinea-	
Bissau ¹	
	Interpretation
Serotyping	
pending in	
Nigeria ¹¹	

Interpretation


SURVEILLAN	CE (Surv.)	, VACCINATION (Vacc.) AND POST VACCINATION MONITORING (PVM)
Country	Activity	Description
Cote d'Ivoire ²		
		Map 8
		Lake Volta ♣Yamoussoukro
		Bingerville Port-Bouët
		Google Earth Date Std, NOAA, U.S. Nevy, MSA, GEBCO 9-2016-0-Cope Image Landate/ Operations 300 km
Ghana ²		
Guinea ²		
Mauritania 2		

Table 10 and Graph 11:

Serotype	Viral lineage	Number of countries where strain is believed to circulate in the 24 countries of Pool 5 - West Africa



Graph 12:




G. POOL 6 – Southern Africa


SURVEILLANCE	E (Surv.), V	ACCINATION (Vacc.) AND POST VACCINATION MONITORING (PVM)
Country	Activity	Description
_		
South Africa		
12		
Zambia ²		

Table 11 and Graph 13:

Serotype	Viral lineage	Number of countries where strain is believed to circulate in the 8 countries of Pool 6 -Southern Africa



Graph 14:




H. POOL 7 – South America

Table 12 and Graph 15:

Serotype	Viral lineage	Number of countries where strain is believed to circulate in the 2 countries of Pool 7 -South America



Graph 16:



V. OTHER NEWS

Thailand¹⁷ –

2

Table 13:

This report provides recommendations of FMDV vaccines to be included in antigen banks. These outputs are generated with a new tool (called PRAGMATIST) that has been developed in partnership between WRLFMD® and EuFMD. These analyses accommodate the latest epidemiological data collected by the OIE FAO FMD Laboratory Network regarding FMDV lineages that are present in different source regions (see Table below), as well as available in vitro, in vivo and field data to score the ability of vaccines to protect against these FMDV lineages.

Lineage	West Eurasia	East Asia	North Africa	India and Southern Asia	East Africa	West and Central Africa	Southern Africa	South America
O ME-SA PanAsia-2	35	-	-	-	-	-	-	-
O ME-SA PanAsia	-	10	-	-	-	-	-	-
O SEA Mya-98	-	33	-	-	-	-	-	-
O ME-SA Ind2001	6	20	35	80	-	-	-	-
O EA or O WA	3	-	20	-	45	37	-	-
O EURO-SA	-	-	-	-	-	-	-	74
O CATHAY	-	10.5	-	-	-	-	-	-
A ASIA Sea-97	-	25	-	-	-	-	-	-
A ASIA Iran-05	25.5	-	-	-	-	-	-	-
A ASIA G-VII	17.5	-	-	16	-	-	-	-
A AFRICA	-	-	35	-	24	25	-	-
A EURO-SA	-	-	-	-	-	-	-	26
Asia-1	12.5	1.5	-	4	-	-	-	-
SAT 1	-	-	-	-	10	10	27	-
SAT 2	0.5	-	10	-	20	28	57	-
SAT 3	-	-	-	-	1		16	-
C	-	-	-	-	_	-	_	-

Vaccine Antigen Prioritisation: Europe

January 2019 DEFINING RISK SELECTING VACCINES Risk Profile: Vaccine Coverage: Vaccine Coverage: O-1039 [MIGH] O-1-Manisa [-IIGH] O-1-Manisa [-IIGH] A-Turi2006 [MIGH] A-Furian-05 [MIGH]

e eight source regions, r Europe (using data for assistance to tailor ita presented is based lividual vaccines.

The table defines the relative distribution of FMDV lineages in each of the while the figure highlights the importance of these *source regions* for collected at the EU-RL Workshop); please contact WRLFMD EuFMD these outputs to other geographical regions. NB: Vaccine-coverage date on available data and may under-represent the true performance of ind

VI. REFERENCES – Superscripts

Dr. Muhammad Afzal

Dr. Wahidullah

Dr. Daniel Gizaw Dr. Kenneth Ketter.

Dr. S. Kremenchugskaya. Dr. S. Saravanan

Dr LE Heath/Ms E Kirkbride

/11	Λ	nn	ех
/ I I .	А	пп	(a)

Description of methods

How to interpret the estimates of the relative prevalence of serotypes and strains:

2.

Pool-level estimates and assumptions:

$$weight_{country \ 1} = \frac{(FMD \ incidence * susceptible \ population)_{country \ 1}}{\sum_{country \ 1}^{country \ 1} (FMD \ incidence * susceptible \ population)}$$

et al

•

•

•

•

$$relative \; prevalence_{serotype \; or \; strain} = \sum_{country \; 1}^{country \; n} \left(weight_{country} * RP_{serotype \; or \; strain} \right)$$

Uncertainty relative to the prevalence of circulating serotypes/strains

High

Medium

Low

Legend of icons in the following tables

•	
•	
•	
0	

Table 14:

				l serotype di				Presumed vira	ıl lineage distribution	n within country				
Country	Last Outbreak Repoted/Serotype#	FMD incidence rate	А	Asia1	o	A/ASIA/SEA- 97	ASIA1/ unnamed	O/ME-SA/Ind-2001	O/SEA/Mya-98	O/ME- SA/PanAsia	O/ME-SA/PanAsia2	O/CATHAY	Uncertainty on circulating serotypes/strains	Reference
			•		0	•				•				
			•		•	•		•	•	•		•		
					•							•		
			•		•	•		•						
			•		•	•			•	•				
					•					•				
					•			•	•	•				
			•	•	•	•	•	•			•			
			•		•	•		•						
					•			•	•	•				
					•							•		
			•		•	•		•	•	•				
			•		•	•		•	•	•		•		

Table 15:

				imed ser ibution v country	vithin	Presumed v	iral lineage distr country	ibution within		
Country	Last Outbreak Repoted/Serotype#	FMD incidence rate							Uncertainty on circulating serotypes/strains	Reference
			•	•	•	•	•	•		
			•		•	•		•		
				0	•		0	•		
			•	•	•	•	•	•		
					•			•		

Table 16:

			Presumed	l serotype d vithin count	istribution ry			Presur							
Country	Last Outbreak Repoted/Serotype#	FMD incidence rate												Uncertainty on circulating serotypes/strains	reference
			•	•	•			•	•		•				
			•		٠		•				•				
			0	•	0		•	0	•		0				
			•		0		•			O	•				
			•	•	•		•	0	•		0				
			0	•	0		•	•	•		0				
			•		•		•				•	•			
			•		•		•			•	•				
			0	O	0		O	•	•		0				
			•		0		•			O	•				
			•	•	•			•	•		•				
			•		•	•	•				•		•		
			•	•	•			•	•		•				
					•							•			
			•		•		•			•	•				
			•		•		•			•	•				
			•		•		•				•				
			•	•	•			•	•		•				
			•		•		•				•				
			0	•	0		•	0	•		0				
			•		0		•			•	•				
			•	•	•		•	•	•		•				

Table 17:

				l serotype di vithin counti			med viral li tion within	_		
Country	Last Outbreak Repoted/Serotype#	FMD incidence rate	Α	0	SAT 2	A/AFRICA	O/EA-3	SAT 2	Uncertainty on circulating serotypes/strains	Reference
			•	•		•	•			
			•	•	•	•	•	•		
			•	•	•	•	•	•		
				•			•			
			•	•		•	•			

Table 18:

			Presu	med ser	otype di countr	stributio Y	n within	Presumed	viral lineage	distribution	within cou	ntry			
Country	Last Outbreak Repoted/Serotype#	FMD incidence rate	А	o	sat1	sat2	sat3	A/AFRICA	O/EA-2	O/EA-3	SAT1	SAT2	SAT3	Uncertainty on circulating serotypes/strains	Reference
			0	•	•	•		•		•	•	•			
				•					•						
			•	•	•		0	•		•	•		0		
			•	•	•		0	•		•	•		0		
			•	•	•		0	•		•	G		0		
			•	•	•	•		•	•		•	•			
			•	•	•	•		•	•		•	•			
			•	•	•		0	•		•	•		0		
				•						•					
			•	•		•		•		•		•			
			•	•	•	•		•		•	•	•			
			•	•	•	•		•	•		•	•			
			•	•	•		0	•		•	•		0		

Table 19:

Country	Last Outbreak Repoted/Serotype#	FMD incidence rate	A	0	sat1	sat2	A/AFRICA	O/EA-3	SAT1	SAT2	Uncertainty on circulating Reference serotypes/strains
			•	•	•	•	•	•	•	•	
			•	•		•	•	•		•	
			•	•		•	•	•		•	
			•	•		G	· ·			G	
			•	•		•	•	•		•	
			0	•		•	•	•		0	
				•		•	•	•		•	
			•	•	•		•	•	•		
				•				•			
			•	•		•	•	•		•	
			•	0		•	•	•		•	
				0		•		•		•	
			•	•		•	•	•		•	
						•				•	
			•	•		•	•	•		•	
			•	•		•	•	•		•	
				•				•			
				•				•		_	

Table 20:

				Presumed serotype distribution within country					Presumed viral lineage distribution within country					
Country	Last Outbreak Repoted/Serotype#	FMD incidence rate	А										Uncertainty on circulating serotypes/strains	Reference
				•	•	0	•		0	•	0	•		
						•					•			
					•	•				•	•			
						•	0				٠	0		
					•	•				•	•			
					0	•				0	•			
			0	•	0	0	•	0	•	0	0	•		
					•	•				•	•			

Table 21:

				d serotype vithin country	Presumed v	viral lineage vithin country		
Country	Last Outbreak Repoted/Serotype#	FMD incidence rate					Uncertainty on circulating serotypes/strains	Reference
			•	•	•	•		
				•		•		



European Commission for the Control of Foot-and-Mouth Disease | fao.eufmd.org